Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aglatimagene besadenovec - Candel Therapeutics

Next Previous
X
Search
Drug Profile

Aglatimagene besadenovec - Candel Therapeutics

Alternative Names: Adenovirus herpes simplex virus thymidine kinase gene therapy - Candel Therapeutics; AdV-Tk; AdV-tk therapy - Candel Therapeutics; ADV/HSV-tk; CAN-2409; CanAtak; Cancer gene therapy - Candel Therapeutics; Gene Mediated Cytotoxic Immunotherapy; GliAtak; GMCI; OncAtak; PancAtak; ProstAtak; TKR therapy - Candel Therapeutics; Virafir

Latest Information Update: 16 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Advantagene
  • Developer Baylor College of Medicine; Bristol-Myers Squibb; Candel Therapeutics; Methodist Healthcare Ministries of South Texas; National Cancer Institute (USA); NYU Langone Medical Center; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  • Class Antineoplastics; Gene therapies; Gene-directed enzyme-prodrug therapies; Immunotherapies; Oncolytic viruses
  • Mechanism of Action Thymidine kinase expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Glioma; Brain cancer
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Prostate cancer
  • Phase II Glioma; Non-small cell lung cancer; Pancreatic cancer; Triple negative breast cancer
  • Phase I/II Glioblastoma; Malignant pleural effusion; Ovarian cancer
  • No development reported Mesothelioma; Oesophageal cancer

Most Recent Events

  • 12 Dec 2024 Candel Therapeutics announces intention to submit a Biologics License Application (BLA) to US FDA for Prostate cancer
  • 11 Dec 2024 Candel Therapeutics plans to initiate discussions with the FDA regarding the regulatory pathway for CAN 2409 in prostate cancer
  • 11 Dec 2024 Candel Therapeutics plans to seek regulatory approval with USFDA in USA for Prostate cancer

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top